Latest Conference Articles

December 8th 2025, 10:44pm

ASH Annual Meeting and Exposition

Triplet therapy with tagraxofusp/azacitidine/venetoclax led to high remission rates and had a safety profile similar to that of tagraxofusp alone in BPDCN.

December 8th 2025, 10:00pm

OncLive News Network: On Location at ASH 2025

Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.

December 8th 2025, 9:30pm

ASH Annual Meeting and Exposition

Sonrotoclax monotherapy led to an ORR of 52.4% and a CR rate of 15.5% in relapsed/refractory MCL.

December 8th 2025, 9:25pm

ASH Annual Meeting and Exposition

The microbiota-based therapy had a favorable safety profile and demonstrated response-driven prolongation of survival in this patient population.

December 8th 2025, 9:04pm

ASH Annual Meeting and Exposition

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

December 8th 2025, 7:47pm

ASH Annual Meeting and Exposition

The 600-mg RP2D of Ziftomenib in combination with venetoclax/azacitidine displayed high response rates in NPM1-mutated AML.

December 8th 2025, 7:28pm

ASH Annual Meeting and Exposition

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

December 8th 2025, 5:00pm

OncLive News Network: On Location at ASH 2025

Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.

December 8th 2025, 4:44pm

ASH Annual Meeting and Exposition

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

December 8th 2025, 4:12pm

ASH Annual Meeting and Exposition

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

December 8th 2025, 3:45pm

ASH Annual Meeting and Exposition

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

December 8th 2025, 3:45pm

ASH Annual Meeting and Exposition

Subcutaneous cevostamab demonstrated activity and safety in patients with multiple myeloma who had received a median of 5 prior lines of therapy.

December 8th 2025, 2:00pm

San Antonio Breast Cancer Symposium

Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.

December 8th 2025, 3:25am

ASH Annual Meeting and Exposition

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

December 8th 2025, 3:00am

ASH Annual Meeting and Exposition

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

December 7th 2025, 10:55pm

ASH Annual Meeting and Exposition

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

December 7th 2025, 10:43pm

ASH Annual Meeting and Exposition

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

December 7th 2025, 9:28pm

ASH Annual Meeting and Exposition

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

December 7th 2025, 8:06pm

ASH Annual Meeting and Exposition

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

December 7th 2025, 7:10pm

ASH Annual Meeting and Exposition

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.